2012
Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease
Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatric Blood & Cancer 2012, 60: 653-658. PMID: 23129068, PMCID: PMC3625668, DOI: 10.1002/pbc.24381.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHU useCell diseaseHematology providersBivariate analysisPediatric sickle cell diseaseBenefits of hydroxyureaMajor therapeutic effectMultivariate logistic regressionLong-term safetyPotential side effectsParental knowledgeBetter parental knowledgeHU usersHydroxyurea useInter-institutional variabilityParents of childrenChildren ages 5Label useSickle genotypeTherapeutic effectClinical careEffective treatmentSide effectsClinical practice
2010
Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease
Oyeku S, Green N, Pashankar F, Giardina P, Mullen C, Driscoll C. Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. Blood 2010, 116: 255. DOI: 10.1182/blood.v116.21.255.255.Peer-Reviewed Original ResearchSickle cell diseaseYears of ageEfficacy of hydroxyureaHU useUse of hydroxyureaMajority of providersCell diseaseSickle cell genotypeProvider barriersClinical indicationsHematology providersNIH Consensus Development ConferencePediatric sickle cell diseaseLong-term side effectsNational evidence-based guidelinesProvider levelBroader clinical indicationsChronic pain useAcute chest syndromePhase III trialsPatients ages 1Dose of hydroxyureaEvidence-based guidelinesOff-label useConsensus Development Conference